<DOC>
	<DOCNO>NCT00034307</DOCNO>
	<brief_summary>This clinical research study design evaluate investigational new medication call sitaxsentan treatment pulmonary arterial hypertension ( patient NYHA functional class II , III IV ) . The purpose study evaluate safety effectiveness two different dos sitaxsentan , compare placebo ( inactive treatment ) treatment pulmonary arterial hypertension . Patients complete trial may eligible take part extension trial ( Protocol FPH01-X ) . Eligible patient receive placebo 12-week study cross receive sitaxsentan extension trial .</brief_summary>
	<brief_title>Safety Efficacy Sitaxsentan Treatment Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sitaxsentan</mesh_term>
	<criteria>1 . NYHA Class II , III IV 2 . 16 75 year age 3 . Specific peak VO2 range 4 . PPH , PAH due connective tissue disease select congenital heart disease 5 . Qualifying cardiac catheterization 6 . History CXR qualify pulmonary function test 7 . History qualify ventilationperfusion lung scan 8 . History qualify echocardiogram 9 . Women childbearing potential must use contraceptive 10 . Stable dose corticosteroid prescribe 1 . Significant lung disease 2 . Chronic liver disease 3 . Uncontrolled sleep apnea 4 . History specific type leave heart disease 5 . Any disorder compromise ability give inform consent 6 . Uncontrolled sleep apnea 7 . Inability perform bicycle exercise test 8 . Ongoing treatment experimental drug device within last 30 day 9 . HIV infection 10 . Specific liver dysfunction 11 . Chronic renal disease 12 . Pregnancy/Nursing 13 . Chronic active hepatitis B C 14 . Chronic Flolan Tracleer use within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2002</verification_date>
</DOC>